NCT02181673 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 239
- group Id
- BG001
- value
- 241
- group Id
- BG002
- value
- 480
- units
- Participants
- groups
- description
- Participants received intravenous infusions of placebo at Weeks 0, 4, 12 and 20.
- id
- BG000
- title
- Placebo (Week 0-24)
- description
- Participants were randomized to receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and every 8 weeks thereafter up to Week 52. At Week 24, participants received a placebo intravenous infusion to maintain the blind.
- id
- BG001
- title
- Golimumab 2 mg/kg
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 216
- group Id
- BG001
- value
- 228
- group Id
- BG002
- value
- 444
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 34
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.53
- value
- 46.7
- group Id
- BG001
- spread
- 11.25
- value
- 45.7
- group Id
- BG002
- spread
- 11.9
- value
- 46.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 118
- group Id
- BG001
- value
- 113
- group Id
- BG002
- value
- 231
- title
- Female
- measurements
- group Id
- BG000
- value
- 121
- group Id
- BG001
- value
- 128
- group Id
- BG002
- value
- 249
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 22
- title
- Belarus
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 22
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 30
- title
- Lithuania
- categories
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 77
- title
- Poland
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Romania
- categories
- measurements
- group Id
- BG000
- value
- 79
- group Id
- BG001
- value
- 74
- group Id
- BG002
- value
- 153
- title
- Russian Federation
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Spain
- categories
- measurements
- group Id
- BG000
- value
- 61
- group Id
- BG001
- value
- 86
- group Id
- BG002
- value
- 147
- title
- Ukraine
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 239
- group Id
- BG001
- value
- 241
- group Id
- BG002
- value
- 480
- units
- Participants
- groups
- description
- Participants received intravenous infusions of placebo at Weeks 0, 4, 12 and 20.
- id
- BG000
- title
- Placebo (Week 0-24)
- description
- Participants were randomized to receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and every 8 weeks thereafter up to Week 52. At Week 24, participants received a placebo intravenous infusion to maintain the blind.
- id
- BG001
- title
- Golimumab 2 mg/kg
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 216
- group Id
- BG001
- value
- 228
- group Id
- BG002
- value
- 444
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 34
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.53
- value
- 46.7
- group Id
- BG001
- spread
- 11.25
- value
- 45.7
- group Id
- BG002
- spread
- 11.9
- value
- 46.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 118
- group Id
- BG001
- value
- 113
- group Id
- BG002
- value
- 231
- title
- Female
- measurements
- group Id
- BG000
- value
- 121
- group Id
- BG001
- value
- 128
- group Id
- BG002
- value
- 249
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 22
- title
- Belarus
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 22
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 30
- title
- Lithuania
- categories
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 77
- title
- Poland
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Romania
- categories
- measurements
- group Id
- BG000
- value
- 79
- group Id
- BG001
- value
- 74
- group Id
- BG002
- value
- 153
- title
- Russian Federation
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Spain
- categories
- measurements
- group Id
- BG000
- value
- 61
- group Id
- BG001
- value
- 86
- group Id
- BG002
- value
- 147
- title
- Ukraine
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle